In today’s session Eli Lilly and Co (LLY) registered an unusually high (541) contracts volume of call trades. Someone, most probably a professional was a very active buyer of the December, 2016 call, expecting serious LLY increase. With 541 contracts traded and 61334 open interest for the Dec, 16 contract, it seems this is a quite bullish bet. The option with symbol: LLY161216C00077500 closed last at: $2.3 or 15.1% down. About 902,385 shares traded hands. Eli Lilly and Co (NYSE:LLY) has declined 0.75% since April 5, 2016 and is downtrending. It has underperformed by 2.71% the S&P500.
Eli Lilly and Co (NYSE:LLY) Ratings Coverage
Out of 15 analysts covering Eli Lilly and Company (NYSE:LLY), 14 rate it a “Buy”, 0 “Sell”, while 1 “Hold”. This means 93% are positive. $125 is the highest target while $75 is the lowest. The $97.88 average target is 33.15% above today’s ($73.51) stock price. Eli Lilly and Company has been the topic of 40 analyst reports since July 23, 2015 according to StockzIntelligence Inc. As per Thursday, November 12, the company rating was maintained by Leerink Swann. Credit Suisse upgraded Eli Lilly and Co (NYSE:LLY) rating on Friday, October 9. Credit Suisse has “Outperform” rating and $105 price target. As per Tuesday, August 2, the company rating was maintained by Argus Research. The rating was upgraded by Barclays Capital to “Overweight” on Tuesday, December 1. The company was maintained on Friday, September 18 by Jefferies. The firm has “Outperform” rating given on Saturday, August 22 by Cowen & Co. The rating was initiated by Berenberg with “Buy” on Thursday, August 27. Bank of America maintained Eli Lilly and Co (NYSE:LLY) rating on Friday, September 18. Bank of America has “Buy” rating and $108.0 price target. BMO Capital Markets upgraded Eli Lilly and Co (NYSE:LLY) rating on Monday, November 16. BMO Capital Markets has “Outperform” rating and $100 price target. Cowen & Co maintained Eli Lilly and Co (NYSE:LLY) on Monday, August 24 with “Outperform” rating.
According to Zacks Investment Research, “Eli Lilly and Company discovers, develops, manufactures, and sells products in one significant business segment -pharmaceutical products. The company directs its research efforts primarily toward the search for products to diagnose, prevent and treat human diseases. The company also conducts research to find products to treat diseases in animals and to increase the efficiency of animal food production.”
Insitutional Activity: The institutional sentiment increased to 1.07 in 2016 Q2. Its up 0.36, from 0.71 in 2016Q1. The ratio improved, as 54 funds sold all Eli Lilly and Co shares owned while 365 reduced positions. 88 funds bought stakes while 362 increased positions. They now own 814.98 million shares or 2.31% less from 834.25 million shares in 2016Q1.
Gulf Retail Bank (Uk) Ltd holds 0.4% of its portfolio in Eli Lilly and Co (NYSE:LLY) for 300,036 shares. Moreover, Stock Yards Financial Bank And Trust has 0.24% invested in Eli Lilly and Co (NYSE:LLY) for 22,976 shares. Calamos Ltd Liability Corp accumulated 0.24% or 432,822 shares. Moreover, Endurance Wealth Mgmt has 0.06% invested in Eli Lilly and Co (NYSE:LLY) for 4,075 shares. State Farm Mutual Automobile Insur accumulated 2.37% or 19.94M shares. Fifth Third State Bank, a Ohio-based fund reported 149,303 shares. Banque Pictet & Cie Sa last reported 0.08% of its portfolio in the stock. Wagner Bowman Mngmt has 0.3% invested in the company for 9,672 shares. Atlanta Grp owns 5,063 shares or 0.09% of their US portfolio. The New York-based Arrow Corp has invested 0.12% in Eli Lilly and Co (NYSE:LLY). Stockman Asset Management holds 26,637 shares or 1.64% of its portfolio. Moreover, Weatherly Asset Mngmt L P has 2.99% invested in Eli Lilly and Co (NYSE:LLY) for 57,930 shares. Nbt Natl Bank N A Ny owns 12,014 shares or 0.17% of their US portfolio. Invest Svcs holds 0.12% or 3,375 shares in its portfolio. Blackhill Capital last reported 156,400 shares in the company.
Insider Transactions: Since May 12, 2016, the stock had 1 insider buy, and 11 sales for $134.99 million net activity. LILLY ENDOWMENT INC had sold 220,000 shares worth $17.13M on Wednesday, June 29. 2,248 shares were sold by Crowe Maria A, worth $182,927 on Tuesday, October 4. The insider Zakrowski Donald A sold 1,213 shares worth $100,873. TAI JACKSON P also bought $205,875 worth of Eli Lilly and Co (NYSE:LLY) shares. Barnes Melissa S also sold $73,180 worth of Eli Lilly and Co (NYSE:LLY) shares.
Eli Lilly and Company is engaged in drug manufacturing business. The company has a market cap of $80.21 billion. The Firm discovers, develops, makes and markets products in two divisions: human pharmaceutical products and animal health products. It has a 31.92 P/E ratio. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.
LLY Company Profile
Eli Lilly and Company, incorporated on January 17, 1901, is engaged in drug manufacturing business. The Firm discovers, develops, makes and markets products in two divisions: human pharmaceutical products and animal health products. The Company’s products are sold in over 120 countries. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists. The Company’s animal health business segment operates through the Company’s Elanco division, which develops, makes and markets products for both food animals and companion animals. The Firm makes and distributes its products through facilities in the United States, Puerto Rico and over 10 other countries.
More notable recent Eli Lilly and Co (NYSE:LLY) news were published by: Fool.com which released: “Better Buy: Eli Lilly and Co vs. Pfizer” on October 26, 2016, also Bloomberg.com with their article: “Eli Lilly’s Diabetes Misery Will Have Company” published on October 26, 2016, Fool.com published: “Better Buy: AbbVie Inc. vs. Eli Lilly & Co.” on August 17, 2016. More interesting news about Eli Lilly and Co (NYSE:LLY) were released by: Nasdaq.com and their article: “Eli Lilly And Co. Q3 Profit Declines 2%” published on October 25, 2016 as well as Seekingalpha.com‘s news article titled: “Eli Lilly & Co. (LLY) Q3 2016 Results – Earnings Call Transcript” with publication date: October 25, 2016.